allendalepharm Chapter 160: Are you In or Are you Out?
Chapter 160: Are you In or Are you Out?
One day earlier, at Michael's penthouse in BGC. He entered the Virtual World and there he found himself in a laboratory with white walls surrounding the room, medical technology lining up the walls, and a central holographic interface displaying various data points and schematics. He navigated through the lab, examining the high-tech equipment that was present there.
He found out that the Virtual World changed according to the kind of blueprint he'd want to inspect. If it's something related to medicine, it will create a virtual world akin to a pharmaceutical laboratory, complete with simulation stations for drug testing and molecular analysis.
When his focus shifted to medical devices, the environment transformed into an engineering workshop, equipped with 3D modeling platforms and prototype testing equipment.
Fascinated by the adaptability of the Virtual World, Michael decided to delve deeper into the Alzheimer's pill project. He initiated a simulation that mimicked the human brain's environment, allowing him to observe how the nanoparticles interacted with amyloid plaques at a microscopic level.
This immersive experience gave him valuable insights into potential improvements in the pill's formulation to enhance its effectiveness.
By the way, he bought the pills for 3,000 System Points. It was quite cheap due to its nature being a pill.
After hours of meticulous work in the virtual lab, Michael transitioned to the cancer treatment pod project. He explored various engineering and design modifications to optimize the pod's functionality. Through interactive simulations, he tested different configurations, analyzing their efficiency in targeting cancer cells while minimizing harm to healthy tissues.
Throughout this process, Michael was not alone. Virtual assistants, powered by advanced AI, provided him with real-time data analysis, research summaries, and technical support.
He found out that the Alzheimer's pill medicine was 99.99 percent effective in reducing amyloid plaques in the simulated brain environment. This result was beyond his initial expectations and highlighted the potential of the pill to make a significant impact on Alzheimer's treatment.
As for the cancer pod, or what he called the Medipod. If you have forgotten, a technology designed to cure all kinds of cancer, was also effective.
Now the problem is the mass production of these miracle drugs and the Medipod. The blueprint is there, the schematics are there, and the manufacturing process is there, but the manufacturing process itself is hard to replicate in the real-world due to the complexity of the machines needed to manufacture these advanced treatments.
The precision required in the fabrication of the nanoparticles for the Alzheimer's pill and the intricate components of the Medipod demanded state-of-the-art manufacturing facilities, which were not introduced yet in this decade.
Michael sighed.
"I have to think of a narrative again," Michael muttered to himself.
To introduce a futuristic technology to this current year, Michael had always been considering the reaction of the public and the specialists. Like for example, how come a mechanical engineering student comes up with a miracle drug without a background in pharmacology or medical science? He knew that credibility would be as crucial as the product itself in the market's eyes.
He paused for effect, then continued, "So, here's the choice I'm giving you: either you trust in my track record and the innovations I've brought to market, and we move forward together, or I will proceed to establish this enterprise on my own. If I go alone, and these technologies succeed, then unfortunately, you won't benefit from the windfall."
He let his words sink in, giving the investors time to ponder the gravity of the decision before them.
"I'm here to change the world," Michael concluded, "and I invite you to be part of this journey. Together, we can create a legacy that will outlive us, a legacy of saving lives and changing the course of medical history. Heck, you might even get yourself a plaque in the hall of fame of Medicine," Michael added with a hint of humor to lighten the mood.
Antoinette and Bridget exchanged looks.
"Ms von Reimann? What do you think about another stunt of Mr. Reyes? Is it going to be the same as his solar panel and the electric vehicle?"
"If you ask me, Michael has a way of turning the impossible into reality," Bridget replied thoughtfully. "His track record with SolaraTech and the electric vehicle innovation speaks volumes. It's risky, yes, but the potential payoff is enormous."
Antoinette nodded slowly, her business acumen kicking in. "The medical sector needs revolutionizing. If Michael's Medipod and miracle pill can deliver as promised, we're looking at a game-changer."
Michael observed the shift in their demeanor. "I'm not asking you to leap blindly," he reassured. "I'm offering you a chance to be at the forefront of medical innovation. Yes, it's a venture that carries risks, but also one that promises significant rewards."
"You make it sound like we're on the brink of a medical renaissance," Antoinette said, a slight smile appearing.
"How much do you need?"
"Investment such as this would require massive capital. I don't think you two can cover it all on your own," Michael interjected, seeing their intrigued yet cautious expressions. "To properly develop, test, and mass-produce the Medipod and the pill, we're looking at an investment of around 20 billion dollars."
The room fell silent at the mention of the amount.
Bridget's eyebrows raised, "Twenty billion? That's a hefty sum, even by our standards."
Michael nodded. "Yes, it is. Of course, you two will be a major shareholder, and then I will look for someone else, someone you can recommend who has the vision and financial strength to participate in this groundbreaking venture. We need partners who are willing to invest in the future, partners who understand the long-term impact of what we are creating."
Antoinette considered Michael's words carefully. "You're talking about bringing in more investors to share the load. That makes sense, given the scale of what you're proposing."
Michael leaned forward, his eyes locking with theirs. "Not only that, I'm ready to invest a significant portion of my personal fortune into this. I believe in it that much. So, are you in, or are you out?"